PMAM
IBRX icon

Penn Mutual Asset Management’s ImmunityBio IBRX Stock Holding History

Penn Mutual Asset Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-21,416
Closed -$508K – 91
2021
Q1 		$508K Buy
+21,416
New +$555K 0.57% 28

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Penn Mutual Asset Management's IBRX Position: Q2 2021 in Review

Penn Mutual Asset Management sold out of ImmunityBio (IBRX) in Q2 2021, closing a stake of 21,416 shares — an estimated $508K sold.

Penn Mutual Asset Management first reported a position in IBRX in Q1 2021 and held it in 1 quarter. The position peaked at $508K in Q1 2021. 125 funds tracked by Wall St. Rank hold IBRX as of Q2 2021.

  • Penn Mutual Asset Management reported no remaining ImmunityBio position as of Q2 2021 after selling out during the quarter.
  • Penn Mutual Asset Management sold 21,416 ImmunityBio shares in Q2 2021, an estimated $508K.
  • Penn Mutual Asset Management first reported a position in ImmunityBio in Q1 2021 and held it in 1 quarter.
  • Penn Mutual Asset Management's ImmunityBio position peaked at $508K in Q1 2021.
  • 125 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2021.

Based on Penn Mutual Asset Management's 13F filing for Q2 2021, filed 26 Aug 2021.